1-4 of 4
Zhirong Zhan
Close
Sort by
Journal Articles

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

Arup R. Chakraborty, Robert W. Robey, Victoria L. Luchenko, Zhirong Zhan, Richard L. Piekarz, Jean-Pierre Gillet, Andrew V. Kossenkov, Julia Wilkerson, Louise C. Showe, Michael M. Gottesman, Nathan L. Collie, Susan E. Bates
Journal: Blood
Blood (2013) 121 (20): 4115–4125.
https://doi.org/10.1182/blood-2012-08-449140
Published: 2013
Includes: Supplemental data
Journal Articles

T-cell lymphoma as a model for the use of histone deacetylase inhibitors in cancer therapy: impact of depsipeptide on molecular markers, therapeutic targets, and mechanisms of resistance

Richard L. Piekarz, Robert W. Robey, Zhirong Zhan, Ganesh Kayastha, Anousheh Sayah, Amina H. Abdeldaim, Sonia Torrico, Susan E. Bates
Journal: Blood
Blood (2004) 103 (12): 4636–4643.
https://doi.org/10.1182/blood-2003-09-3068
Published: 2004
Journal Articles

Genetic Polymorphism in MDR-1 : A Tool for Examining Allelic Expression in Normal Cells, Unselected and Drug-Selected Cell Lines, and Human Tumors

Lyn A. Mickley, Jong-Seok Lee, Zheng Weng, Zhirong Zhan, Manuel Alvarez, Wyndham Wilson, Susan E. Bates, Tito Fojo
Journal: Blood
Blood (1998) 91 (5): 1749–1756.
https://doi.org/10.1182/blood.V91.5.1749
Published: 1998
Journal Articles

Expression of the Multidrug Resistance-Associated Protein Gene in Refractory Lymphoma: Quantitation by a Validated Polymerase Chain Reaction Assay

Zhirong Zhan, Victor A. Sandor, Erick Gamelin, Joanna Regis, Bruce Dickstein, Wyndham Wilson, Antonio T. Fojo, Susan E. Bates
Journal: Blood
Blood (1997) 89 (10): 3795–3800.
https://doi.org/10.1182/blood.V89.10.3795
Published: 1997